ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of “Moderate Buy” from Analysts

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has earned a consensus recommendation of “Moderate Buy” from the seventeen research firms that are covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $25.56.

A number of equities analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $27.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 target price on shares of ACADIA Pharmaceuticals in a report on Thursday, November 7th. Raymond James reissued a “market perform” rating on shares of ACADIA Pharmaceuticals in a report on Thursday, October 10th. Finally, StockNews.com lowered ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 14th.

ACADIA Pharmaceuticals Stock Performance

NASDAQ ACAD opened at $17.28 on Friday. The business’s fifty day moving average is $15.72 and its 200 day moving average is $16.07. ACADIA Pharmaceuticals has a fifty-two week low of $14.15 and a fifty-two week high of $32.59. The company has a market capitalization of $2.88 billion, a PE ratio of 22.15 and a beta of 0.40.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.06. The firm had revenue of $250.40 million for the quarter, compared to analysts’ expectations of $248.83 million. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%. The business’s quarterly revenue was up 18.3% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.40) EPS. On average, sell-side analysts forecast that ACADIA Pharmaceuticals will post 0.73 EPS for the current year.

Insider Activity at ACADIA Pharmaceuticals

In other news, insider James Kihara sold 4,073 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total value of $68,467.13. Following the sale, the insider now directly owns 19,863 shares in the company, valued at approximately $333,897.03. This represents a 17.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Mark C. Schneyer sold 10,259 shares of the stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total value of $172,453.79. Following the completion of the sale, the chief financial officer now owns 53,302 shares in the company, valued at approximately $896,006.62. The trade was a 16.14 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 24,661 shares of company stock valued at $414,551. Insiders own 28.30% of the company’s stock.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Several large investors have recently modified their holdings of the business. Park Place Capital Corp acquired a new position in ACADIA Pharmaceuticals during the 3rd quarter valued at about $25,000. Values First Advisors Inc. purchased a new stake in shares of ACADIA Pharmaceuticals during the third quarter worth about $27,000. Quest Partners LLC increased its holdings in shares of ACADIA Pharmaceuticals by 42.3% during the third quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 1,047 shares in the last quarter. Stonepine Capital Management LLC purchased a new position in shares of ACADIA Pharmaceuticals in the 2nd quarter valued at approximately $81,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of ACADIA Pharmaceuticals by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,999 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 1,066 shares during the last quarter. Institutional investors own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.